@article{ea828a60af0c49039e4cfc7b2ccad6fa,
title = "Decision tree classification of cognitive functions with D2 receptor occupancy and illness severity in late-life schizophrenia",
keywords = "Antipsychotics, Cognition, Dopamine D receptor, Machine learning, Schizophrenia, [C]Raclopride",
author = "Keisuke Kusudo and Ryo Ochi and Shinichiro Nakajima and Takefumi Suzuki and David Mamo and Fernando Caravaggio and Wanna Mar and Philip Gerretsen and Masaru Mimura and Pollock, {Bruce G.} and Mulsant, {Benoit H.} and Ariel Graff-Guerrero and Rajji, {Tarek K.} and Hiroyuki Uchida",
note = "Funding Information: Dr. Gerretsen reports receiving research support from the Canadian Institute of Health Research (CIHR), Ontario Ministry of Health and Long-Term Care, Ontario Mental Health Foundation (OMHF), and the Centre for Addiction and Mental Health (CAMH). Funding Information: Dr. Mimura has received speaker's honoraria from Byer Pharmaceutical, Daiichi Sankyo, Dainippon-Sumitomo Pharma, Eisai, Eli Lilly, Fuji Film RI Pharma, Hisamitsu Pharmaceutical, Janssen Pharmaceutical, Kyowa Pharmaceutical, Mochida Pharmaceutical, MSD, Mylan EPD, Nihon Medi-physics, Nippon Chemipher, Novartis Pharma, Ono Yakuhin, Otsuka Pharmaceutical, Pfizer, Santen Pharmaceutical, Shire Japan, Takeda Yakuhin, Tsumura, and Yoshitomi Yakuhin within the past three years. Also, he received grants from Daiichi Sankyo, Eisai, Pfizer, Shionogi, Takeda, Tanabe Mitsubishi and Tsumura within the past three years outside the submitted work. Funding Information: This work was supported by Canadian Institutes of Health Research (CIHR) MOP-97946 (AG-G, DM, BP, BHM), US- National Institutes of Health (NIH) RO1MH084886 (AG-G, DM, BP, BHM), CIHR fellowship (SN), Government of Canada Post-Doctoral Research Fellowships (TS), Japan Society for the Promotion of Science (SN), and Japanese Society of Clinical Neuropsychopharmacology (TS). These grant agencies did not influence study design, data acquisition and analysis, or journal selection for submission. Funding Information: Dr. Mulsant holds and receives support from the Labatt Family Chair in Biology of Depression in Late-Life Adults at the University of Toronto. He currently receives research support from Brain Canada, the Canadian Institutes of Health Research, the CAMH Foundation, the Patient-Centered Outcomes Research Institute (PCORI), the US National Institute of Health (NIH), Capital Solution Design LLC (software used in a study founded by CAMH Foundation), and HAPPYneuron (software used in a study founded by Brain Canada). He has been an unpaid consultant to Myriad Neuroscience. Within the past three years, he has also received research support from Eli Lilly (medications for a NIH-funded clinical trial) and Pfizer (medications for a NIH-funded clinical trial). He has been an unpaid consultant to Myriad Neuroscience. Funding Information: Dr. Uchida has received grants from Eisai, Otsuka Pharmaceutical, Dainippon-Sumitomo Pharma, and Meiji-Seika Pharma; speaker's honoraria from Otsuka Pharmaceutical, Dainippon-Sumitomo Pharma, Eisai, and Meiji-Seika Pharma; and advisory panel payments from Dainippon-Sumitomo Pharma within the past three years. ",
year = "2022",
month = mar,
doi = "10.1016/j.schres.2022.01.044",
language = "English",
volume = "241",
pages = "113--115",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
}
